8-K Announcements
6Material company update
Feb 25, 2026·SEC
Material company update
Nov 6, 2025·SEC
Material company update
Oct 27, 2025·SEC
Maravai LifeSciences Holdings, Inc.(MRVI)Earnings, Financials & Key Ratios
MRVI•NASDAQ
$3.94
$436M mkt cap·Price updated May 7, 2026
AboutMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.Show more
- Revenue$50M-80.8%
- EBITDA-$230M-28.8%
- Net Income-$131M+9.7%
- EPS (Diluted)-0.24+77.1%
- Gross Margin25.75%-38.4%
- EBITDA Margin-461.59%-569.3%
- Operating Margin-431.69%-374.9%
- Net Margin-262.25%-369.3%
- ROE-27.53%-29.9%
- ROIC-39.24%-61.8%
- Debt/Equity0.10-85.4%
MRVI Key Insights
Maravai LifeSciences Holdings, Inc. (MRVI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 29.4% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MRVI Price & Volume
Maravai LifeSciences Holdings, Inc. (MRVI) stock price & volume — 10-year historical chart
Loading chart...
MRVI Growth Metrics
Maravai LifeSciences Holdings, Inc. (MRVI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-29.39%
3 Years-61.63%
TTM-28.34%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM12.37%
Return on Capital
10 Years5.09%
5 Years3.73%
3 Years-15.83%
Last Year-25.67%
MRVI Recent Earnings
Maravai LifeSciences Holdings, Inc. (MRVI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 25, 2026EPS
$0.04
Est $0.07
+42.9%
Revenue
$50M
Est $49M
+1.7%
Q4 2025
Nov 6, 2025EPS
$0.08
Est $0.06
-33.3%
Revenue
$42M
Est $49M
-15.1%
Q3 2025
Aug 11, 2025EPS
$0.08
Est $0.06
-33.3%
Revenue
$47M
Est $50M
-5.4%
Q2 2025
May 12, 2025EPS
$0.08
Est $0.07
-14.3%
Revenue
$47M
Est $44M
+6.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.04vs $0.07+42.9% | $50Mvs $49M+1.7% |
| Q4 2025 | Nov 6, 2025 | $0.08vs $0.06-33.3% | $42Mvs $49M-15.1% |
| Q3 2025 | Aug 11, 2025 | $0.08vs $0.06-33.3% | $47Mvs $50M-5.4% |
| Q2 2025 | May 12, 2025 | $0.08vs $0.07-14.3% | $47Mvs $44M+6.5% |
Based on last 12 quarters of dataView full earnings history →
MRVI Peer Comparison
Maravai LifeSciences Holdings, Inc. (MRVI) competitors in Life Science Tools and Reagents — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AZTA | 855.36M | 18.57 | -15.22 | 3.55% | -29.86% | -10.69% | 0.06 | |
 NUVL | 7.53B | 102.40 | -17.50 | -42.78% | ||||
 BCAB | 5.12M | 4.35 | -0.09 | -81.82% | -29.8% | |||
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 | |
 TWST | 3.65B | 58.54 | -45.03 | 20.32% | -19.85% | -17.46% | 0.29 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare MRVI vs Peers
Maravai LifeSciences Holdings, Inc. (MRVI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRVI Income Statement
Maravai LifeSciences Holdings, Inc. (MRVI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 123.83M | 143.14M | 284.1M | 799.24M | 883M | 288.94M | 259.19M | 49.87M |
| Revenue Growth % | - | 15.59% | 98.48% | 181.33% | 10.48% | -67.28% | -10.3% | -80.76% |
| Cost of Goods Sold | 60.77M | 66.85M | 79.65M | 140.56M | 168.96M | 148.74M | 150.88M | 37.02M |
| COGS % of Revenue | 49.07% | 46.7% | 28.04% | 17.59% | 19.13% | 51.48% | 58.21% | 74.25% |
| Gross Profit | 63.07M▲ 0% | 76.29M▲ 21.0% | 204.45M▲ 168.0% | 658.68M▲ 222.2% | 714.04M▲ 8.4% | 140.2M▼ 80.4% | 108.31M▼ 22.7% | 12.84M▼ 88.1% |
| Gross Margin % | 50.93% | 53.3% | 71.96% | 82.41% | 80.87% | 48.52% | 41.79% | 25.75% |
| Gross Profit Growth % | - | 20.97% | 167.99% | 222.17% | 8.41% | -80.37% | -22.75% | -88.14% |
| Operating Expenses | 45.69M | 52.3M | 84.55M | 104.03M | 139.83M | 171.85M | 343.93M | 411.72M |
| OpEx % of Revenue | 36.9% | 36.54% | 29.76% | 13.02% | 15.84% | 59.48% | 132.7% | 825.65% |
| Selling, General & Admin | 41.19M | 48.35M | 94.25M | 100.06M | 129.26M | 151.39M | 161.77M | 187.86M |
| SG&A % of Revenue | 33.27% | 33.78% | 33.17% | 12.52% | 14.64% | 52.39% | 62.42% | 376.73% |
| Research & Development | 4.5M | 3.63M | 9.3M | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| R&D % of Revenue | 3.63% | 2.53% | 3.27% | 1.9% | 2.08% | 5.98% | 7.42% | 46.78% |
| Other Operating Expenses | 87K | 322K | -19M | -11.25M | -7.8M | 3.18M | 162.93M | 200.53M |
| Operating Income | 16.44M▲ 0% | 23.99M▲ 45.9% | 119.9M▲ 399.8% | 554.64M▲ 362.6% | 574.22M▲ 3.5% | -31.65M▼ 105.5% | -235.62M▼ 644.5% | -215.27M▲ 8.6% |
| Operating Margin % | 13.27% | 16.76% | 42.2% | 69.4% | 65.03% | -10.95% | -90.91% | -431.69% |
| Operating Income Growth % | - | 45.95% | 399.84% | 362.58% | 3.53% | -105.51% | -644.49% | 8.64% |
| EBITDA | 38.78M | 48.07M | 145.74M | 579.4M | 612.32M | 17.13M | -178.75M | -230.18M |
| EBITDA Margin % | 31.32% | 33.58% | 51.3% | 72.49% | 69.35% | 5.93% | -68.97% | -461.59% |
| EBITDA Growth % | - | 23.95% | 203.17% | 297.56% | 5.68% | -97.2% | -1143.32% | -28.77% |
| D&A (Non-Cash Add-back) | 22.35M | 24.08M | 25.84M | 24.75M | 38.1M | 48.78M | 56.87M | -14.91M |
| EBIT | 10.9M | 24.11M | 112.44M | 561.02M | 571.89M | 663.63M | -213.78M | 0 |
| Net Interest Income | -27.4M | -29.96M | -30.74M | -30.26M | -18.08M | -18.16M | -20.3M | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 2.34M | 27.73M | 27.4M | -6.67M |
| Interest Expense | 27.4M | 29.96M | 30.74M | 30.26M | 20.41M | 45.89M | 47.7M | -26.86M |
| Other Income/Expense | -32.93M | -29.84M | -38.21M | -23.88M | -22.74M | 649.38M | -25.86M | -19.71M |
| Pretax Income | -16.5M▲ 0% | -5.85M▲ 64.5% | 81.7M▲ 1495.8% | 530.76M▲ 549.7% | 551.47M▲ 3.9% | 617.74M▲ 12.0% | -261.48M▼ 142.3% | -234.97M▲ 10.1% |
| Pretax Margin % | -13.32% | -4.09% | 28.76% | 66.41% | 62.45% | 213.79% | -100.89% | -471.21% |
| Income Tax | 417K | -652K | 2.88M | 61.52M | 60.81M | 756.11M | -1.86M | -57.37M |
| Effective Tax Rate % | -2.53% | 11.14% | 3.53% | 11.59% | 11.03% | 122.4% | 0.71% | 24.41% |
| Net Income | -17.73M▲ 0% | -8.49M▲ 52.1% | 76.89M▲ 1006.1% | 182.04M▲ 136.8% | 220.21M▲ 21.0% | -119.03M▼ 154.1% | -144.85M▼ 21.7% | -130.77M▲ 9.7% |
| Net Margin % | -14.32% | -5.93% | 27.06% | 22.78% | 24.94% | -41.19% | -55.89% | -262.25% |
| Net Income Growth % | - | 52.14% | 1006.06% | 136.76% | 20.97% | -154.05% | -21.69% | 9.72% |
| Net Income (Continuing) | -16.91M | -5.2M | 78.82M | 469.25M | 490.66M | -138.38M | -259.62M | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 3.61M | 3.23M | 66.23M | 229.86M | 360.02M | 373.13M | 251.92M | 160.33M |
| EPS (Diluted) | -0.20▲ 0% | -0.05▲ 73.1% | 2.36▲ 4486.6% | 1.56▼ 33.9% | 1.67▲ 7.1% | -0.90▼ 153.9% | -1.05▼ 16.7% | -0.24▲ 77.1% |
| EPS Growth % | - | 73.1% | 4486.62% | -33.9% | 7.05% | -153.89% | -16.67% | 77.14% |
| EPS (Basic) | -0.20 | -0.05 | 7.43 | 1.59 | 1.67 | -0.90 | -1.05 | -0.24 |
| Diluted Shares Outstanding | 88.97M | 96.65M | 96.65M | 121.97M | 131.69M | 131.92M | 137.91M | 145.07M |
| Basic Shares Outstanding | 88.97M | 96.65M | 96.65M | 114.79M | 131.54M | 131.92M | 137.91M | 145.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
MRVI Balance Sheet
Maravai LifeSciences Holdings, Inc. (MRVI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 53.8M | 60.55M | 331.6M | 740.04M | 847.9M | 699.91M | 429.15M | 296.25M |
| Cash & Short-Term Investments | 21.87M | 24.7M | 236.18M | 551.27M | 632.14M | 574.96M | 322.4M | 216.89M |
| Cash Only | 21.87M | 24.7M | 236.18M | 551.27M | 632.14M | 574.96M | 322.4M | 216.89M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 15.99M | 18.03M | 51.02M | 117.51M | 146.81M | 55.72M | 38.52M | 25.5M |
| Days Sales Outstanding | 47.13 | 45.98 | 65.55 | 53.67 | 60.69 | 70.39 | 54.25 | 186.64 |
| Inventory | 14.31M | 14.2M | 33.3M | 51.56M | 43.15M | 51.4M | 50.08M | 40.49M |
| Days Inventory Outstanding | 85.94 | 77.54 | 152.61 | 133.88 | 93.22 | 126.12 | 121.16 | 399.22 |
| Other Current Assets | 0 | 800K | 0 | 0 | 25.8M | 17.83M | 18.14M | 13.37M |
| Total Non-Current Assets | 485.87M | 517.24M | 939.09M | 1.18B | 1.43B | 787.54M | 579.1M | 69.92M |
| Property, Plant & Equipment | 42.58M | 94.31M | 101.31M | 95.43M | 116.59M | 222.65M | 217.03M | 1.22M |
| Fixed Asset Turnover | 2.91x | 1.52x | 2.80x | 8.38x | 7.57x | 1.30x | 1.19x | 41.01x |
| Goodwill | 224.28M | 224.28M | 224.28M | 152.77M | 283.67M | 326.03M | 159.88M | 68.71M |
| Intangible Assets | 218.13M | 197.85M | 177.66M | 117.57M | 216.66M | 220.99M | 194.96M | 151.54M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 11.36M | 8.56M | 0 | 0 |
| Other Non-Current Assets | 894K | 805K | 4.16M | 4.36M | 40.33M | 9.32M | 7.24M | 0 |
| Total Assets | 539.68M▲ 0% | 577.8M▲ 7.1% | 1.27B▲ 119.9% | 1.92B▲ 51.0% | 2.28B▲ 19.0% | 1.49B▼ 34.8% | 1.01B▼ 32.2% | 770.58M▼ 23.6% |
| Asset Turnover | 0.23x | 0.25x | 0.22x | 0.42x | 0.39x | 0.19x | 0.26x | 0.06x |
| Asset Growth % | - | 7.06% | 119.92% | 50.96% | 18.98% | -34.83% | -32.22% | -23.57% |
| Total Current Liabilities | 35.92M | 29.56M | 130.78M | 93.78M | 110.14M | 87.47M | 56.97M | 44.92M |
| Accounts Payable | 3.6M | 7.48M | 2.98M | 8.15M | 5.99M | 10.73M | 11.96M | 0 |
| Days Payables Outstanding | 21.65 | 40.83 | 13.68 | 21.17 | 12.94 | 26.33 | 28.93 | - |
| Short-Term Debt | 2.5M | 2.5M | 6M | 6M | 5.44M | 5.44M | 5.44M | 5.44M |
| Deferred Revenue (Current) | 1.09M | 841K | 78.06M | 12.64M | 3.09M | 3.36M | 3.29M | 0 |
| Other Current Liabilities | 22.17M | 11.08M | 4.17M | 18.89M | 69.48M | 47.62M | 0 | 39.48M |
| Current Ratio | 1.50x | 2.05x | 2.54x | 7.89x | 7.70x | 8.00x | 7.53x | 6.60x |
| Quick Ratio | 1.10x | 1.57x | 2.28x | 7.34x | 7.31x | 7.41x | 6.65x | 5.69x |
| Cash Conversion Cycle | 111.43 | 82.69 | 204.47 | 166.37 | 140.97 | 170.19 | 146.48 | - |
| Total Non-Current Liabilities | 355.74M | 403.61M | 985.17M | 1.28B | 1.27B | 610.1M | 374.06M | 352.95M |
| Long-Term Debt | 335.55M | 334.78M | 528.61M | 524.59M | 522M | 518.71M | 290.49M | 30.14M |
| Capital Lease Obligations | 1.84M | 52.92M | 56.17M | 40.91M | 51.56M | 79.41M | 72.49M | 0 |
| Deferred Tax Liabilities | 15.86M | 14.7M | 8.61M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.5M | 1.21M | 391.78M | 713.64M | 693.38M | 11.98M | 11.09M | 322.81M |
| Total Liabilities | 391.66M | 433.17M | 1.12B | 1.37B | 1.38B | 697.57M | 431.04M | 397.87M |
| Total Debt | 339.89M | 390.2M | 590.78M | 575.22M | 585.26M | 610.97M | 376.69M | 35.58M |
| Net Debt | 318.02M | 365.5M | 354.6M | 23.95M | -46.88M | 36.01M | 54.29M | -181.31M |
| Debt / Equity | 2.30x | 2.70x | 3.82x | 1.05x | 0.65x | 0.77x | 0.65x | 0.10x |
| Debt / EBITDA | 8.76x | 8.12x | 4.05x | 0.99x | 0.96x | 35.66x | - | - |
| Net Debt / EBITDA | 8.20x | 7.60x | 2.43x | 0.04x | -0.08x | 2.10x | - | - |
| Interest Coverage | 0.60x | 0.80x | 3.90x | 18.33x | 28.13x | -0.69x | -4.94x | - |
| Total Equity | 148.02M▲ 0% | 144.63M▼ 2.3% | 154.75M▲ 7.0% | 545.36M▲ 252.4% | 905.24M▲ 66.0% | 789.88M▼ 12.7% | 577.21M▼ 26.9% | 372.71M▼ 35.4% |
| Equity Growth % | - | -2.29% | 7% | 252.42% | 65.99% | -12.74% | -26.92% | -35.43% |
| Book Value per Share | 1.66 | 1.50 | 1.60 | 4.47 | 6.87 | 5.99 | 4.19 | 2.57 |
| Total Shareholders' Equity | 144.41M | 141.4M | 88.51M | 315.5M | 545.22M | 416.75M | 325.29M | 212.38M |
| Common Stock | 182.81M | 183.91M | 2.58M | 2.55M | 2.55M | 2.51M | 2.53M | 2.56M |
| Retained Earnings | -38.24M | -42.38M | 854K | 184.56M | 404.77M | 285.74M | 140.89M | 10.12M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -167K | -133K | -44K | 0 | 0 | 0 | 0 | 524K |
| Minority Interest | 3.61M | 3.23M | 66.23M | 229.86M | 360.02M | 373.13M | 251.92M | 160.33M |
MRVI Cash Flow Statement
Maravai LifeSciences Holdings, Inc. (MRVI) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -186K | 24.11M | 152.19M | 368.57M | 535.98M | 126.22M | 7.46M | -57.57M |
| Operating CF Margin % | -0.15% | 16.85% | 53.57% | 46.12% | 60.7% | 43.68% | 2.88% | -115.46% |
| Operating CF Growth % | - | 13065.05% | 531.09% | 142.18% | 45.42% | -76.45% | -94.09% | -871.24% |
| Net Income | -16.91M | -5.2M | 78.82M | 469.25M | 490.66M | -119.03M | -259.62M | -230.76M |
| Depreciation & Amortization | 22.35M | 24.08M | 25.84M | 24.75M | 38.1M | 48.78M | 56.87M | 0 |
| Stock-Based Compensation | 2.12M | 1.68M | 24.63M | 10.46M | 18.67M | 34.59M | 49.41M | 0 |
| Deferred Taxes | 317K | -1.16M | -5.46M | 46.9M | 42.32M | 754.94M | 2.32M | -4.21M |
| Other Non-Cash Items | 7.79M | 2.42M | -7.52M | -6.16M | -8.7M | -690.9M | 171.1M | 177.4M |
| Working Capital Changes | -15.84M | 2.29M | 35.89M | -176.63M | -45.08M | 97.84M | -12.61M | 0 |
| Change in Receivables | -4.15M | -1.89M | -33.14M | -70.39M | -22.27M | 84.39M | 14.36M | 0 |
| Change in Inventory | 2.31M | 106K | -19.1M | -21.57M | 9.46M | 649K | 377K | 0 |
| Change in Payables | -871K | 2.47M | 1.18M | 676K | -1.58M | 5.28M | 723K | 0 |
| Cash from Investing | -3.45M | -17.15M | 6.07M | 105.66M | -267.61M | -122.31M | -24.32M | -31.41M |
| Capital Expenditures | -3.61M | -17.15M | -25.41M | -14.85M | -17.09M | -65.55M | -29.66M | 0 |
| CapEx % of Revenue | 2.92% | 11.98% | 8.94% | 1.86% | 1.94% | 22.69% | 11.44% | 26.37% |
| Acquisitions | 160K | 0 | -3.02M | 119.96M | -238.35M | -69.62M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 160K | 0 | 34.5M | 548K | -12.17M | 12.87M | 5.34M | -31.41M |
| Cash from Financing | -9.17M | -4.17M | 53.21M | -159.05M | -187.5M | -61.09M | -235.71M | -16.5M |
| Debt Issued (Net) | 55.43M | -2.64M | 196.92M | -6M | -5.44M | -5.77M | -234.07M | 0 |
| Equity Issued (Net) | -9K | -227K | -1000K | 1000K | 1000K | -20K | -1000K | 0 |
| Dividends Paid | -52.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -9K | -227K | -1.46B | 0 | 0 | -20K | -2.08M | 0 |
| Other Financing | -12.53M | -1.3M | -100.91M | -154.76M | -184.42M | -55.3M | 443K | -16.5M |
| Net Change in Cash | -12.87M▲ 0% | 2.83M▲ 122.0% | 211.48M▲ 7362.4% | 315.09M▲ 49.0% | 80.87M▼ 74.3% | -57.18M▼ 170.7% | -252.56M▼ 341.7% | -105.51M▲ 58.2% |
| Free Cash Flow | -3.8M▲ 0% | 6.97M▲ 283.5% | 126.78M▲ 1719.7% | 353.72M▲ 179.0% | 518.89M▲ 46.7% | 60.67M▼ 88.3% | -22.19M▼ 136.6% | -70.72M▼ 218.7% |
| FCF Margin % | -3.07% | 4.87% | 44.63% | 44.26% | 58.76% | 21% | -8.56% | -141.82% |
| FCF Growth % | - | 283.49% | 1719.71% | 179.01% | 46.69% | -88.31% | -136.58% | -218.67% |
| FCF per Share | -0.04 | 0.07 | 1.31 | 2.90 | 3.94 | 0.46 | -0.16 | -0.49 |
| FCF Conversion (FCF/Net Income) | 0.01x | -2.84x | 1.98x | 2.02x | 2.43x | -1.06x | -0.05x | 0.44x |
| Interest Paid | 25.68M | 28.73M | 28.92M | 27.23M | 20.2M | 0 | 50.97M | 0 |
| Taxes Paid | 97K | 802K | 5.01M | 22.47M | 23.03M | 0 | 670K | 0 |
MRVI Key Ratios
Maravai LifeSciences Holdings, Inc. (MRVI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -11.98% | -5.8% | 51.37% | 52% | 30.36% | -14.04% | -21.19% | -27.53% |
| Return on Invested Capital (ROIC) | 2.65% | 3.69% | 17.64% | 77.13% | 60.33% | -2.82% | -24.25% | -39.24% |
| Gross Margin | 50.93% | 53.3% | 71.96% | 82.41% | 80.87% | 48.52% | 41.79% | 25.75% |
| Net Margin | -14.32% | -5.93% | 27.06% | 22.78% | 24.94% | -41.19% | -55.89% | -262.25% |
| Debt / Equity | 2.30x | 2.70x | 3.82x | 1.05x | 0.65x | 0.77x | 0.65x | 0.10x |
| Interest Coverage | 0.60x | 0.80x | 3.90x | 18.33x | 28.13x | -0.69x | -4.94x | - |
| FCF Conversion | 0.01x | -2.84x | 1.98x | 2.02x | 2.43x | -1.06x | -0.05x | 0.44x |
| Revenue Growth | - | 15.59% | 98.48% | 181.33% | 10.48% | -67.28% | -10.3% | -80.76% |
MRVI SEC Filings & Documents
Maravai LifeSciences Holdings, Inc. (MRVI) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRVI Frequently Asked Questions
Maravai LifeSciences Holdings, Inc. (MRVI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Maravai LifeSciences Holdings, Inc. (MRVI) reported $185.7M in revenue for fiscal year 2025. This represents a 50% increase from $123.8M in 2018.
Maravai LifeSciences Holdings, Inc. (MRVI) saw revenue decline by 80.8% over the past year.
Maravai LifeSciences Holdings, Inc. (MRVI) reported a net loss of $130.8M for fiscal year 2025.
Dividend & Returns
Maravai LifeSciences Holdings, Inc. (MRVI) has a return on equity (ROE) of -27.5%. Negative ROE indicates the company is unprofitable.
Maravai LifeSciences Holdings, Inc. (MRVI) had negative free cash flow of $45.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates